OSSIOfiber® Threaded Trimmable Fixation Nail

K241277 · OSSIO , Ltd. · HWC · Jul 3, 2024 · Orthopedic

Device Facts

Record IDK241277
Device NameOSSIOfiber® Threaded Trimmable Fixation Nail
ApplicantOSSIO , Ltd.
Product CodeHWC · Orthopedic
Decision DateJul 3, 2024
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3040
Device ClassClass 2
AttributesTherapeutic, Pediatric

Intended Use

OSSIOfiber® Threaded Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, arthrodesis, and bone grafts, of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/ or immobilization in adults and children (2-12 vears) and adolescents (12-21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation.

Device Story

Degradable bone fixation implant; composed of poly (L-lactide) (PLDLA) reinforced with continuous mineral fibers. Used for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis, and bone grafts. Implanted by orthopedic surgeons in clinical settings. Principle of operation: provides mechanical fixation; degrades via hydrolysis into alpha-hydroxy acids and minerals found in natural bone; load transfers to surrounding anatomy during healing; eliminates need for hardware removal surgery. Supplied sterile for single-patient use. Compatible with standard orthopedic surgical tools (ISO 9714).

Clinical Evidence

Bench testing only. Mechanical pull-out testing performed to verify fixation and strength properties compared to additional predicates (K203465, K231272), both initially and following in-vitro degradation. Biocompatibility and MR safety established in primary predicate submission (K233198).

Technological Characteristics

Material: degradable poly (L-lactide) (PLDLA) reinforced with continuous mineral fibers. Form factor: threaded cannulated nail. Sterilization: Ethylene Oxide (EtO). Compatibility: ISO 9714 surgical instruments. Degradation profile: substantial degradation within ~18 months.

Indications for Use

Indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis, and bone grafts in upper extremity, fibula, knee, ankle, and foot. Patient population: adults, children (2-12 years), and adolescents (12-21 years) where growth plates are fused or not crossed by fixation. Requires brace/immobilization.

Regulatory Classification

Identification

A smooth or threaded metallic bone fixation fastener is a device intended to be implanted that consists of a stiff wire segment or rod made of alloys, such as cobalt-chromium-molybdenum and stainless steel, and that may be smooth on the outside, fully or partially threaded, straight or U-shaped; and may be either blunt pointed, sharp pointed, or have a formed, slotted head on the end. It may be used for fixation of bone fractures, for bone reconstructions, as a guide pin for insertion of other implants, or it may be implanted through the skin so that a pulling force (traction) may be applied to the skeletal system.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" stacked on top of each other. July 3, 2024 OSSIO Ltd. % Dave McGurl Vice President, Regulatory Affairs- Orthopedics MCRA. LLC 803 7th Street NW, Third Floor Washington, District of Columbia 20001 Re: K241277 Trade/Device Name: OSSIOfiber® Threaded Trimmable Fixation Nail Regulation Number: 21 CFR 888.3040 Regulation Name: Smooth Or Threaded Metallic Bone Fixation Fastener Regulatory Class: Class II Product Code: HWC Dated: May 6, 2024 Received: May 6, 2024 Dear Mr. McGurl: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" {1}------------------------------------------------ # K241277 - Dave Mcgurl (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100. Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). # Sincerely, # Shumaya Ali -S Shumaya Ali, M.P.H. Assistant Director DHT6C: Division of Restorative, Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health {2}------------------------------------------------ # Indications for Use Submission Number (if known) K241277 Device Name OSSIOfiber® Threaded Trimmable Fixation Nail #### Indications for Use (Describe) OSSIOfiber® Threaded Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, arthrodesis, and bone grafts, of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/ or immobilization in adults and children (2-12 vears) and adolescents (12-21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation. Type of Use (Select one or both, as applicable) > Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) # CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. # *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ #### 510(k) SUMMARY #### OSSIOfiber® Threaded Trimmable Fixation Nail #### Submitter #### Ossio Ltd. 8 HaTochen Street, Caesarea, Israel, 3079861 Phone: +972-4-9986600 Facsimile: +972-4-9986601 Contact Person: Taly Lindner Date Prepared: June 27, 2024 ## Regulatory Contact Dave McGurl Vice President, Regulatory Affairs - Orthopedics MCRA, LLC 803 7th St NW, Floor 3 Washington, DC 20001 Office: 202.552.5800 Name of Device: OSSIOfiber® Threaded Trimmable Fixation Nail Common or Usual Name: Screw, Fixation, Bone Classification Name: Smooth or threaded metallic bone fixation fastener Regulatory Class: Class II, 21 C.F.R. § 888.3040 Product Code: HWC #### Predicate Devices OSSIOfiber® Threaded Trimmable Fixation Nail (K233198) - Primary Predicate OSSIOfiber® Cannulated Trimmable Fixation Nail (K203465, K231272) - Additional Predicate #### Purpose of the Submission This traditional 510(k) premarket notification is being submitted to allow for additional compatible instrumentation for the OSSIOfiber® Threaded Trimmable Fixation Nails cleared in K233198. #### Device Description The OSSIOfiber® Threaded Trimmable Fixation Nails are threaded cannulated bone fixation implants made of degradable poly (L-lactide) (PLDLA) reinforced with continuous mineral fibers. The polymer content degrades by hydrolysis into alpha-hydroxy acids that are metabolized by the body. The fibers are made of minerals that are found in natural bone. As the OSSIOfiber implants degrade, the load transfers to the surrounding anatomy throughout the healing period of the osteotomy, fusion, or fracture. Substantial degradation takes place within approximately 18 months as shown in pre-clinical studies, thus eliminating the requirement for future hardware removal surgery. The OSSIOfiber® Threaded Trimmable Fixation Nails are supplied sterile, for single patient use only. The implants are available in several sizes and designs. {4}------------------------------------------------ The OSSIOfiber® Threaded Trimmable Fixation Nails are designed to be used with commonly available orthopedic surgical tools such as ISO 9714 compatible instruments. #### Indications for Use OSSIOfiber® Threaded Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis, and bone grafts, of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/or immobilization in adults and children (2-12 years) and adolescents (12-21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation. ## Summary of Technological Characteristics The OSSIOfiber® Threaded Trimmable Fixation Nails, have identical intended use, indications for use, material composition, design characteristic, principles of operation, manufacturing and sterilization methods (sterilized by EtO) as the primary predicate device (K233198). The subject device has identical intended use, material composition, principles of operation, manufacturing and sterilization methods, and similar indications for use and design characteristic as the additional predicate device (K203465, K231272). Although there are differences between the subject device and the additional predicate device in regards to design, mechanical pull-out testing demonstrated at least equivalent performance both initially and after in vitro degradation. Any differences between OSSIOfiber® Threaded Trimmable Fixation Nail and its predicate devices do not raise different questions of safety and effectiveness. ## Non-Clinical Data Mechanical pull-out testing was performed to verify the fixation and strength properties of the OSSIOfiber® Threaded Trimmable Fixation Nail, and to compare them to those of the additional predicate device (K203465, K231272). Testing was done initially and following in-vitro degradation. Biocompatibility and magnetic resonance (MR) safety compatibility was established within the primary predicate submission (K233198). #### Conclusions The OSSIOfibe® Threaded Trimmable Fixation Nails are as safe and effective as their predicate devices. The OSSIOfiber® Threaded Trimmable Fixation Nails, have identical intended use, indications for use, material composition, design characteristic, principles of operation, manufacturing and sterilization methods (sterilized by EtO) as the primary predicate device (K233198). The subject device has identical intended use, material composition, principles of operation, manufacturing and sterilization methods, and similar indications for use and design characteristic as the additional predicate device (K203465, K231272). Any minor design differences relative to the additional predicate do not alter the intended surgical use of the device and do not affect its safety and effectiveness when used as labeled. Non-clinical testing data demonstrate that the OSSIOfiber® Threaded Trimmable Fixation Nails are at least as safe and effective as their predicate devices (K233198, K203465, K231272). Thus, the OSSIOfiber® Threaded Trimmable Fixation Nails are substantially equivalent to it's predicate devices.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%